苏州欧米尼医药

Omni Pharmaceutical is a leading Chinese innovative pharmaceutical company specializing in the development, manufacturing, and commercialization of high-barrier respiratory drug delivery technologies and inhalation preparations. Founded in 2011, the company has established advanced technology platforms covering four major inhalation modalities: dry powder inhalers (DPI), metered-dose inhalers (MDI), nebulizer solutions, and nasal sprays, alongside proprietary respiratory device design capabilities such as its Ouxichang device. Omni Pharmaceutical focuses primarily on chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), with a robust pipeline designed to provide high-quality, affordable alternatives to imported therapies. In August 2025, the company achieved a major commercial milestone with the NMPA approval of Shifeikang (Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation), a generic alternative to GSK's Seretide. Headquartered with an R&D center in Shanghai, Omni operates state-of-the-art manufacturing facilities in Taicang and Haimen, Jiangsu Province, and is actively expanding its presence into international regulated markets.